arrow_back Back to App

Drug Manufacturing Innovation: Faster Access to New Therapies

This new act aims to support the development and adoption of innovative drug manufacturing methods. This could lead to faster and more efficient drug production, potentially meaning quicker access to new, safer, and more effective therapies for citizens. The program also seeks to improve the quality and safety of available pharmaceutical products.
Key points
Support for innovative drug manufacturing methods, potentially accelerating the introduction of new therapies.
Improved communication and collaboration among scientists, companies, and government agencies to advance pharmaceutical technologies.
Availability of grants and contracts for entities developing new drug manufacturing technologies.
Issuance of guidance for companies to facilitate the use of new technologies and compliance with safety requirements.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_6988
Sponsor: Rep. Levin, Mike [D-CA-49]
Process start date: 2022-03-08
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Drug Manufacturing Innovation Act of 2022

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_6988.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2022-03-08.

What are the main provisions?

Key points include:

  • Support for innovative drug manufacturing methods, potentially accelerating the introduction of new therapies.
  • Improved communication and collaboration among scientists, companies, and government agencies to advance pharmaceutical technologies.
  • Availability of grants and contracts for entities developing new drug manufacturing technologies.
  • Issuance of guidance for companies to facilitate the use of new technologies and compliance with safety requirements.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Levin, Mike [D-CA-49].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

CATEGORIES

Health